RECELL®
Autologous Cell Harvesting Device

RE-PIGMENTATION AFTER TREATMENT OF A FACIAL BURN WITH USE OF RECELL®

CASE STUDY

Nicole Kopari, MD / Department of Surgery at the University of California San Francisco, Fresno, CA

PATIENT PRESENTATION

A 54-year-old male sustained a 4.5% total body surface area (TBSA) flame burn to the face after a water heater exploded.



Treatment Day



Treatment Day



6 Days Post-treatment

1 Month Post-treatment



TREATMENT REGIMEN

After initial debridement, the patient's wound was treated with xenograft. Twelve days after the initial burn injury, the wound was excised and Spray-On Skin™ Cells were prepared using the RECELL System (Figures A & B). The cell suspension was applied directly over the prepared wound bed. The area was dressed with Telfa™ Clear, followed by Xeroform™.

CLINICAL OUTCOME

The wound was healed by post-treatment Day 6 (Figure C). At 1 month post-treatment the patient experienced breakdown on the forehead with superimposed infection (Figure D). However, the wound showed restoration of pigmentation and close pigmentation match to surrounding skin without significant areas of hyper/hypopigmentation. Subsequent follow-ups (not pictured) showed continued improvement in restoration of pigment. The clinician noted that pliability and durability of the RECELL-treated area was similar to surrounding non-injured skin.

CONCLUSION

This case report shows healing and re-pigmentation achieved with Spray-On Skin Cells, even after 12 days of non-progressive healing with traditional treatment regimens (i.e., xenograft). Treatment with RECELL resulted in wound closure at post-treatment Day 6, and positive outcomes including close pigmentation match to surrounding skin and absence of hyper/hypopigmentation.

RECELL®
Autologous Cell Harvesting Device

INSIDE BURN PATIENTS' SKIN CELLS ARE REGENERATIVE FORCES AT THE READY.

GIVE THEM THE SIGNAL TO MOVE.

Visit RECELLsystem.com to learn more.

IMPORTANT SAFETY INFORMATION

INDICATIONS FOR USE: The RECELL® Autologous Cell Harvesting Device is indicated for the treatment of acute thermal burn wounds in patients 18 years of age and older. The RECELL® device is used by an appropriately licensed healthcare professional at the patient's point of care to prepare autologous RES® Regenerative Epidermal Suspension for direct application to acute partial-thickness thermal burn wounds or application in combination with meshed autografting for acute full-thickness thermal burn wounds.
CONTRAINDICATIONS: RECELL® is contraindicated for the treatment of wounds clinically diagnosed as infected or with necrotic tissue present in the wound bed. RECELL® is contraindicated for the treatment of patients with a known hypersensitivity to trypsin or compound sodium lactate solution (Hartmann's Solution). The skin sample collection procedure specified for use of RECELL® should not be used with patients having a known hypersensitivity to anesthetics, adrenaline/epinephrine, povidone-iodine, or chlorhexidine solutions.
WARNINGS: Autologous use only. Wound beds treated with a cytotoxic agent (e.g., silver sulfadiazine) should be rinsed prior to application of the cell suspension. RECELL® is provided sterile and is intended for single use. Do not use RECELL® or device components if packaging is damaged, there are signs of tampering or date of use is beyond the stated expiration date. Choose a skin sample donor site that shows no evidence of surrounding cellulitis or infection. The skin sample should be processed immediately after harvesting. If a skin sample is harvested and processed according to these instructions, it should require between 15 and 30 minutes of contact with the Enzyme. Contact in excess of 60 minutes is not recommended. RECELL® Enzyme is animal derived and freedom from infectious agents cannot be guaranteed.
PRECAUTIONS: RECELL® is not intended to be used alone (i.e., without meshed autograft) for treatment of full-thickness burn wounds. The safety and effectiveness of RECELL® used alone (i.e., without meshed autograft) have not been established for treatment of partial-thickness burn wounds: on the hands and articulated joints, >320 cm2, in patients with wounds totaling >20% Total Body Surface Area (TBSA). The safety and effectiveness of RECELL® plus autografting have not been established for treatment of full-thickness burn wounds: on the hands and articulated joints, in patients with wounds totaling >50% Total Body Surface Area (TBSA).
SPECIAL PATIENT POPULATIONS: The safety and effectiveness of RECELL® have not been established for treatment of acute thermal partial-thickness or full-thickness burn wounds in pediatric patients younger than 18 years of age.

For complete Important Safety Information, refer to Instructions for Use at RECELLSystem.com.

RECELL®
Autologous Cell Harvesting Device

RECELL is a registered trademark of AVITA Medical. Telfa Clear and Xeroform Occlusive Petrolatum Gauze are trademarks of Covidien.
© 2021 AVITA Medical. All rights reserved. MA_Case037_REV2

avita medical